PHARMACY

FDA gives tentative approval to Perrigo’s generic Epiduo Gel

BY David Salazar
SILVER SPRING, Md. — The Food and Drug Administration has given its tentative approval for Perrigo’s generic of Epiduo Gel (adapalene and benzoyl peroxide 0.1%/2.5%), the company announced Thursday. The drug is indicated to treat acne vulgaris in patients 12 years of age and older. 
 
Annual sales for the product were $379 million for the 12 months ended July 2016. 
 
“This tentative approval is another example of Perrigo's ongoing commitment to developing high-quality value alternatives in important treatment categories,” Perrigo CEO John Hendrickson said. 
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Iceshot aims to revolutionize the diabetic community

BY Gina Acosta

ADDISON, Texas — There's a new reusable applicator that freezes injection sites to reduce pain and discomfort, and it's targeted specifically at people with diabetes. 

Iceshot is a personal, topical, dermal numbing unit that is used to numb the skin prior to taking insulin injections.  Within a few quick seconds of holding Iceshot to the skin, the pain of the injections is eased dramatically.

USES:  

Temporarily relieves pain associated with insulin injections.

DIRECTIONS:

1. Remove Iceshot unit from freezer and remove cap
2. Hold Iceshot to skin for thirty seconds or until numb
3. Proceed with normal injection method in the Iceshot affected area
4. Recap and place Iceshot unit back in freezer

Iceshot is a registered medical device with the Food and Drug Administration.  

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Novo Nordisk names new CEO

BY Michael Johnsen

BAGSVAERD, Denmark – Novo Nordisk on Thursday announced that Lars Rebien Sørensen, president and CEO, will retire from the company by the end of 2016. Lars Fruergaard Jørgensen, currently EVP and head of corporate development, will succeed him, effective Jan. 1, 2017.

The company also announced a number of other executive-level changes, effective immediately.

"Succeeding Lars, who during 16 years as CEO of Novo Nordisk has spearheaded Novo Nordisk into a global, very successful and highly respected pharmaceutical company, is a tall order," stated Göran Ando, chairman Novo Nordisk. "The decision to appoint Lars Fruergaard Jørgensen as new CEO is the result of a rigorous process during which a number of qualified candidates were considered," he continued. "With his track record of creating results, driving change and being a role model for the Novo Nordisk Way of running a company, the Board is confident that he is the perfect successor to Lars Rebien Sørensen. In his new role, he will be charged with leading Novo Nordisk through a time of extraordinary change in healthcare systems around the world, with the company's long-term strategy, the Triple Bottom Line business principle and long-term financial targets as his guiding posts."

The boards of the Novo Nordisk Foundation and the Foundation's holding company, Novo A/S, will nominate Lars Rebien Sørensen to become a member of the two boards in March 2017.

In addition, Novo Nordisk announced that Jakob Riis, currently EVP and head of Region China, Pacific & Marketing, is appointed EVP and head of North America Operations. He succeeds Jesper Høiland, who steps down from executive management and whose future role in Novo Nordisk will be announced at a later date.

Maziar Mike Doustdar, currently EVP and head of International Operations, continues in this role, but with enlarged responsibility for an expanded International Operations unit, now covering all territories except for North America and organized in the following five regions: Europe; Latin America; Africa, Asia, Middle East & Oceania; Japan & Korea; and Region China.

Jerzy Gruhn, currently EVP and head of Europe, steps down from executive management and will continue as head of Europe, now as SVP, reporting to Maziar Mike Doustdar.

Lars Fruergaard Jørgensen joined Novo Nordisk in 1991 as an economist in Health Care, Economy & Planning and has over the years completed overseas postings in the Netherlands, U.S. and Japan. In 2004 he was appointed SVP for IT & Corporate Development. In January 2013 he was appointed EVP and chief information officer assuming responsibility for IT, Quality & Corporate Development. In November 2014 he took over additional responsibilities for Corporate People & Organisation and Business Assurance.

Lars Fruergaard Jørgensen is chairman of the board of NNE Pharmaplan A/S, Denmark. He earned an MSc in Finance and Business Administration from Aarhus School of Business, Aarhus University, Denmark, in 1991. He is a Danish national, born November 1966.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?